Diagnosis and Management of Hypoparathyroidism – Evidence‑Based Guideline Summary

1. Diagnostic Criteria

• Confirm hypoparathyroidism on two separate occasions at least two weeks apart by demonstrating low or inappropriately normal albumin‑corrected (or ionized) calcium together with low or inappropriately normal PTH levels【2】.
• Low‑normal ionized calcium (≈1.2 mmol/L) with a PTH that fails to rise (e.g., ≈10 pg/mL) is diagnostic of inappropriate PTH secretion【4】.
• Serum magnesium must be measured and corrected immediately because hypomagnesemia can suppress PTH and mimic hypoparathyroidism【2】.
• Discontinue high‑dose biotin (>5 mg/day) at least three days before repeat PTH testing, as biotin interferes with many immunoassays【2】.

2. Etiology Assessment

Postsurgical Hypoparathyroidism

• Represents ≈75 % of cases; inquire about any recent anterior neck surgery, especially thyroidectomy or parathyroidectomy【6】.
• A postoperative PTH < 10 pg/mL measured 12–24 h after thyroidectomy predicts permanent hypoparathyroidism【2】.
• Chronic (permanent) hypoparathyroidism is confirmed when hypocalcemia persists ≥12 months after surgery【2】.

Nonsurgical Causes

• Autoimmune disease targeting the parathyroid glands (isolated or part of polyglandular autoimmunity) is the second most common cause【6】.
• Genetic testing is recommended for all patients with idiopathic hypoparathyroidism, particularly those with a family history or onset before age 40【2】.

3. Baseline Comprehensive Evaluation

Biochemical Panel

• Serum phosphate – expect hyperphosphatemia.
• Serum magnesium, 25‑hydroxyvitamin D, 1,25‑dihydroxyvitamin D – essential for diagnosis and management【1】.
• Renal function – BUN, creatinine, and estimated GFR.
• 24‑hour urine collection for calcium, creatinine, oxalate, and citrate to assess urinary calcium excretion【2】.

Target‑Organ Assessment for Complications

• Renal imaging (ultrasound or CT) to detect nephrolithiasis or nephrocalcinosis【2】.
• Ophthalmologic exam for cataracts【2】.
• Brain CT if neuropsychiatric symptoms have been present >5 years【2】.
• 12‑lead ECG to screen for QTc prolongation【1】.
• DXA scan, bone turnover markers, and spinal radiographs for skeletal health【2】.
• Skull X‑ray to identify basal ganglia calcifications【5】.

Additional Assessments

• Screen for depression, anxiety, and other neuropsychiatric manifestations; evaluate quality of life【2】.
• Recognize an increased susceptibility to infections (upper‑respiratory, urinary, urogenital)【2】.

4. Treatment Goals

5. Conventional Pharmacologic Therapy

• Oral calcium carbonate 1–2 g elemental calcium three times daily with meals【1】.
• Active vitamin D (calcitriol or alfacalcidol) initiated at a low dose and titrated according to clinical response【1】.
• Target low‑normal albumin‑corrected serum calcium while avoiding overt hypercalcemia【1】.
• Aim for 24‑hour urine calcium <250 mg (women) or <300 mg (men) to reduce renal risk【1】.
• Thiazide diuretics may be added if hypercalciuria persists despite optimal calcium/vitamin D dosing【5】.

6. Monitoring Protocol

7. Common Pitfalls to Avoid

• Do not target normal or high‑normal serum calcium – this raises the risk of hypercalciuria and renal complications【1】.
• Do not overlook magnesium deficiency; it must be corrected to allow appropriate PTH activity【2】.
• Do not ignore 24‑hour urine calcium monitoring; hypercalciuria can occur even with low‑normal serum calcium【1】.
• Active vitamin D increases both serum phosphorus and urinary calcium, requiring careful dose titration【1】.
• Recognize that conventional therapy may not fully relieve symptoms or improve quality of life despite achieving biochemical targets【1】.

8. Indications for Advanced Therapy (PTH Replacement)

• Persistent symptom burden or inadequate control of hypocalcemia【2】.
• Inability to maintain target calcium levels within the low‑normal range【1】.
• Ongoing hypercalciuria with a high risk of renal complications【7】.
• High pill burden that compromises adherence and quality of life【1】.

Evidence: PTH replacement improves physical health‑related quality of life and reduces the need for calcium and active vitamin D, but may increase the risk of hypercalcemia【2】.